Adocia to Participate in Upcoming Investor Conferences

Lyons, France, November 10, 2016 – Adocia (Euronext Paris: FR0011184241 – ADOC), a clinical stage biopharmaceutical company focused on diabetes treatment with innovative formulations of approved proteins, today announced that Dr. Gérard Soula, the Company’s Chairman and Chief Executive Officer, will be participating in two upcoming investor conferences. The details for both conferences are provided below.

Jefferies 2016 Global Healthcare Conference

Date: November 16 – 17, 2016
Location: The Waldorf Hilton Hotel, London
Presentation Date and Time: November 16, 2016 at 3:20 pm (GMT)

During this presentation, Dr. Soula has been invited to provide an overview of the Company’s business strategy and recent developments.

Oppenheimer 2016 Life Sciences Summit

Date: November 29, 2016
Location: Sofitel Hotel, New York City

The Summit’s meeting format will feature Dr. Soula and Mr. Steve Daly, Adocia US General Manager, participating in one-on-one meetings with investors.

About ADOCIA

Adocia is a clinical-stage biotechnology company that specializes in the development of innovative formulations of already-approved therapeutic proteins. Adocia’s insulin formulation portfolio, featuring four clinical-stage products and one preclinical product, is among the largest and most differentiated in the industry.

The proprietary BioChaperone® technological platform is designed to enhance the effectiveness and/or safety of therapeutic proteins while making them easier for patients to use. Adocia customizes BioChaperone to each protein for a given application in order to address specific patient needs.

Adocia’s clinical pipeline includes four novel insulin formulations for the treatment of diabetes: two ultra-rapid formulations of insulin analogs (BioChaperone Lispro U100 and U200), a rapid-acting formulation of human insulin (HinsBet U100) and a combination of basal insulin glargine and rapid-acting insulin lispro (BioChaperone Combo). Adocia is also developing an aqueous formulation of human glucagon (BioChaperone Human Glucagon), two combinations of insulin glargine with GLP-1s (BioChaperone Glargine Dulaglutide and BioChaperone Glargine Liraglutide) and a concentrated, rapid-acting formulation of human insulin (HinsBet US00), all of which are in
preclinical development.

In December 2014, Adocia signed a partnership with Eli Lilly for the development and commercialization of the BioChaperone Lispro projects.

Adocia aims to deliver “Innovative medicine for everyone, everywhere.”

To learn more about Adocia, please visit us at www.adocia.com

For more information please contact:

<table>
<thead>
<tr>
<th>Adocia</th>
<th>Adocia Press Relations Europe</th>
<th>Adocia Investor Relations USA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gérard Soula</td>
<td>Raimund Gabriel</td>
<td>The Ruth Group</td>
</tr>
<tr>
<td>Chairman and CEO</td>
<td></td>
<td>Tram Bui</td>
</tr>
<tr>
<td><a href="mailto:contactinvestisseurs@adocia.com">contactinvestisseurs@adocia.com</a></td>
<td><a href="mailto:raimund.gabriel@mc-services.eu">raimund.gabriel@mc-services.eu</a></td>
<td><a href="mailto:tbui@theruthgroup.com">tbui@theruthgroup.com</a></td>
</tr>
<tr>
<td>Phone: +33 4 72 610 610</td>
<td><a href="mailto:adocia@mc-services.eu">adocia@mc-services.eu</a></td>
<td>Phone: +1 646 536 7035</td>
</tr>
</tbody>
</table>

Disclaimer

This press release contains certain forward-looking statements concerning Adocia and its business. Such forward-looking statements are based on assumptions that Adocia considers to be reasonable. However, there can be no assurance that the estimates contained in such forward-looking statements will be verified, which estimates are subject to numerous risks including the risks set forth in the ‘Risk Factors’ section of the Reference Document registered by the French Autorité des marchés financiers on April 30, 2015 under number R.15-032 (a copy of which is available on www.adocia.com) and to the development of economic conditions, financial markets and the markets in which Adocia operates. The forward-looking statements contained in this press release are also subject to risks not yet known to Adocia or not currently considered material by Adocia. The occurrence of all or part of such risks could cause actual results, financial conditions, performance or achievements of Adocia to be materially different from such forward-looking statements.

This press release and the information contained herein do not constitute an offer to sell or the solicitation of an offer to buy Adocia shares in any jurisdiction.